STOCK TITAN
  1. Home
  2. News
  3. ARQT

Arcutis Biotherapeutics Inc - ARQT STOCK NEWS

Welcome to our dedicated news page for Arcutis Biotherapeutics (Ticker: ARQT), a resource for investors and traders seeking the latest updates and insights on Arcutis Biotherapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Arcutis Biotherapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Arcutis Biotherapeutics's position in the market.

News
Majority of Individuals with Atopic Dermatitis Improved with Arcutis’ Roflumilast Cream 0.15% According to New Data from Phase 3 Program
Rhea-AI Summary
Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) announced new patient response data for roflumilast cream 0.15% at the 2024 Winter Clinical Dermatology Conference. The data showed that 91.5% of individuals treated with the cream had a measurable improvement in Eczema Area and Severity Index (EASI) in 4 weeks. The cream demonstrated statistically significant improvement in EASI scores compared to the vehicle. Dr. Lawrence Eichenfield and Dr. Patrick Burnett provided positive comments on the efficacy and reliability of roflumilast cream for atopic dermatitis.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
clinical trial
-
News
FDA Approves Arcutis’ ZORYVE® (roflumilast) Topical Foam, 0.3% for the Treatment of Seborrheic Dermatitis in Individuals Aged 9 Years and Older
Rhea-AI Summary
Arcutis Biotherapeutics, ticker symbol ARQT, has received FDA approval for ZORYVE (roflumilast) topical foam, 0.3% for the treatment of seborrheic dermatitis in individuals 9 years of age and older. ZORYVE foam provides rapid disease clearance and significant reduction in itch, with nearly 80% of individuals achieving the primary efficacy endpoint of IGA Success and just over 50% of individuals reaching complete clearance at Week 8 in the STRATUM trial. This is the first drug approved for seborrheic dermatitis with a new mechanism of action in over two decades. Seborrheic dermatitis affects more than 10 million people in the United States, and the commercial product is expected to be available by the end of January. Arcutis Biotherapeutics will host a conference call on Monday, December 18 at 8:30 a.m. EST to discuss the approval.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
fda approval
-
News
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) granted 90,500 restricted stock units and 106,500 stock options to 7 newly hired employees under the 2022 Inducement Plan. The restricted stock units and options vest over four years, subject to continuous employment. The stock options have a ten-year term and an exercise price of $1.99 per share.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
News
FDA Accepts Arcutis’ Supplemental New Drug Application for Roflumilast Cream 0.15% for the Treatment of Atopic Dermatitis in Adults and Children Down to Age 6
Rhea-AI Summary
Arcutis Biotherapeutics, Inc. (ARQT) announced that the FDA has accepted its supplemental new drug application for roflumilast cream 0.15% for the treatment of atopic dermatitis in adults and children down to age 6. The FDA has set a PDUFA target action date of July 07, 2024. Roflumilast cream is a once-daily, steroid-free, phosphodiesterase-4 (PDE4) inhibitor. The sNDA is supported by positive efficacy and safety data from the pivotal Phase 3 INTEGUMENT-1 and INTEGUMENT-2 trials. The company aims to provide a new topical option for the millions of Americans living with atopic dermatitis, potentially becoming the new standard of care in the treatment of the condition.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.86%
Tags
clinical trial
-
News
Arcutis Announces Third Quarter 2023 Financial Results and Provides Business Update
Rhea-AI Summary
Arcutis Biotherapeutics reported total revenues of $38.1 million in Q3 2023, with net product revenues for ZORYVE cream reaching $8.1 million, a 70% increase compared to Q2 2023. The company received FDA approval for the expanded indication of ZORYVE in plaque psoriasis for children down to the age of 6. Arcutis also made progress in its atopic dermatitis program with the submission of a supplemental New Drug Application and positive trial results. The company appointed new executives and strengthened its balance sheet with a $100 million follow-on offering.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.91%
Tags
earnings
-
News
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Arcutis Biotherapeutics, Inc. has granted 52,500 restricted stock units of its common stock to eight newly hired employees. The awards were approved by the Compensation Committee and granted under the 2022 Inducement Plan. The restricted stock units vest over four years, with 25% vesting on each annual anniversary of the vesting commencement date.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.91%
Tags
none
News
Arcutis to Report Third Quarter 2023 Financial Results
Rhea-AI Summary
Arcutis Biotherapeutics, Inc. will host a conference call and webcast on November 3, 2023, to report its third quarter financial results and provide a business update.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.42%
Tags
conferences earnings
-
News
New Data Shows ZORYVE® (Roflumilast) Cream 0.3% Provided Measurable Improvement of Plaque Psoriasis in Nearly All Individuals in DERMIS Trials
Rhea-AI Summary
Arcutis Biotherapeutics announces new data showing significant improvement in Psoriasis Area and Severity Index (PASI) scores with ZORYVE cream
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-18.65%
Tags
none
-
News
Arcutis Announces Pricing of $100 Million Public Offering
Rhea-AI Summary
Arcutis Biotherapeutics, Inc. announces pricing of public offering of common stock and pre-funded warrants
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-18.65%
Tags
offering
News
Arcutis Announces Proposed Public Offering
Rhea-AI Summary
Arcutis Biotherapeutics announces underwritten public offering of $100.0 million of common stock
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-18.65%
Tags
offering
Stock ARQT logo
Arcutis Biotherapeutics Inc

Nasdaq:ARQT

ARQT Rankings

#2364 Ranked by Market Cap
#5426 Ranked by Stock Gains
N/A Ranked by Dividends

ARQT Stock Data

1.16B
74.79M
2.5%
95.84%
16.75%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States
Westlake Village

About ARQT

arcutis biotherapeutics, inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. its lead product candidate is arq-151, a topical cream formulation of roflumilast that is in phase iii clinical trials for the treatment of plaque psoriasis and atopic dermatitis. the company is also developing arq-154, a topical foam formulation of arq-151 for the treatment of seborrheic dermatitis and scalp psoriasis; arq-252, a selective topical small molecule inhibitor of janus kinase type 1 for hand eczema and other inflammatory dermatoses; and arq-255, a topical formulation of arq-252 designed to reach deeper into the skin to the postulated site of inflammation in alopecia areata. the company was formerly known as arcutis, inc. and changed its name to arcutis biotherapeutics, inc. in october 2019. arcutis biotherapeutics, inc. was founded in 2016 and is headquartered in westlake village, california.